Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Bausch Health Companies (BHC) and Insulet (PODD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Bausch Health Companies (BHC – Research Report) and Insulet (PODD – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medtronic (MDT)
Citi analyst Joanne Wuensch reiterated a Buy rating on Medtronic yesterday. The company’s shares closed last Wednesday at $98.49.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $112.93, a 17.6% upside from current levels. In a report issued on February 12, Barclays also resumed coverage with a Buy rating on the stock with a $116.00 price target.
See the top stocks recommended by analysts >>
Bausch Health Companies (BHC)
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Sell rating on Bausch Health Companies, with a price target of $5.00. The company’s shares closed last Wednesday at $6.19.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Bausch Health Companies has an analyst consensus of Hold, with a price target consensus of $7.75.
Insulet (PODD)
Bank of America Securities analyst Travis Steed reiterated a Buy rating on Insulet yesterday and set a price target of $360.00. The company’s shares closed last Wednesday at $258.07.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Insulet is a Strong Buy with an average price target of $368.41, a 38.5% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $285.00 price target.
